Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Hradec Kralove – page 3

191 clinical trials in Hradec Kralove, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Hradec Kralove at a glance
191
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

191 trials in Hradec Kralove

Open in trial search

Plasma cell myeloma

Recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Recruiting

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Follicular lymphoma

Recruiting

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Colitis ulcerative

Recruiting

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years

Plasma cell myeloma

Recruiting

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Grifols Therapeutics LLC

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Hereditary angioedema

Recruiting

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Mantle cell lymphoma

Recruiting

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Hradec Kralove

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative research focusing on inflammatory bowel diseases, including studies evaluating new therapies for both ulcerative colitis and Crohn's disease. Clinical trials are investigating advanced treatments like OD-07656 and TAK-279 for managing moderate to severe cases.

  • Ulcerative Colitis Treatment
  • Crohn's Disease Management
  • Clostridioides difficile Studies

Additional research explores antibiotic optimization and novel therapeutic combinations.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for metastatic prostate cancer and advanced gastric cancers. Research focuses on innovative therapies combining targeted treatments with immunotherapy approaches.

  • Prostate Cancer Therapeutics
  • Gastric Cancer Treatment
  • Melanoma Interventions

Investigations include novel drug combinations and immunotherapy strategies.

03 Neurological Conditions

Advanced research in multiple sclerosis and Parkinson's disease, evaluating new therapeutic approaches and comparing treatment efficacies. Studies include assessments of innovative medications and comparative analyses.

  • Multiple Sclerosis Treatments
  • Parkinson's Disease Therapy
  • Stroke Management

Focus on both disease-modifying treatments and symptom management.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.